Breakthru Medicine
Founded 2024
About Breakthru Medicine
Breakthru Medicine is a biotechnology company that develops novel therapeutic modalities aimed at treating cancer by targeting hard-to-drug disease mechanisms. The company’s work spans multiple drug formats, including small molecules, antibody-drug conjugate payloads, and molecular glues, with efforts focused on expanding molecular targets relevant to oncology. Breakthru Medicine’s research approach integrates diverse therapeutic technologies to explore treatment avenues where current options show limited effectiveness. It engages scientific teams to design and progress potential therapies through preclinical development. The company’s development strategy centers on identifying promising clinical programs early and refining its pipeline accordingly.
Company Facts
- Founded: 2024
- Operating status: Active
- IPO status: Private
- Employees: 11 – 50
- Total funding: $60.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2026)
- Website: https://www.breakthrumed.com/
Social Profiles
Canonical: https://fsome.com/organization/breakthru-medicine-8559491 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.